Compare Aurora Cannabis Inc (ACB) vs Allstate Corp (ALL) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Allstate (ALL) trades at $251.46, up 0.45% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 5.49, net income margin of 17.98%, and consistent earnings beats in recent quarters. Recent news highlights Q2 2026 earnings anticipation and dividend declarations, reinforcing positive sentiment.

Outlook remains favorable given valuation discounts and earnings strength, though risks include potential hurricane impacts and market volatility. Analyst consensus leans bullish with a $249.50 price target, suggesting near-term stability with upside potential from continued operational execution.